[1] ABDULRAHIM A H，FULTON R L，SUCHAREW

H，et al. National institutes of health stroke scale

item profiles as predictor of patient outcome：

external validation on independent trial data[J].

Stroke，2015，46（2）：395-400.

[2] ADAMS H P Jr，BENDIXEN B H，KAPPELLE L

J，et al. Classification of subtype of acute ischemic

stroke. Definitions for use in a multicenter clinical

trial. TOAST. Trial of Org 10172 in Acute Stroke

Treatment[J]. Stroke，1993，24（1）：35-41.

[3] BAMFORD J，SANDERCOCK P，JONES L，et

al. The natural history of lacunar infarction：the

Oxfordshire Community Stroke Project[J]. Stroke，

1987，18（3）：545-551.

[4] Lavallée P C，Labreuche J，Faille D，et al.

Circulating markers of endothelial dysfunction

and platelet activation in patients with severe

symptomatic cerebral small vessel disease[J].

Cerebrovasc Dis，2013，36（2）：131-138.

[5] KOLOMINSKY-RABAS P L，WEBER M，

GEFELLER O，et al. Epidemiology of ischemic

stroke subtypes according to TOAST criteria：

incidence，recurrence，and long-term survival

in ischemic stroke subtypes：a population-based

study[J]. Stroke，2001，32（12）：2735-2740.

[6] WANG J，BIE J，GHOSH S. Intracellular cholesterol

transport proteins enhance hydrolysis of HDL-CEs

and facilitate elimination of cholesterol into bile[J]. J

Lipid Res，2016，57（9）：1712-1719.

[7] MARQUES L R，DINIZ T A，ANTUNES B

M，et al. Reverse cholesterol transport：molecular

mechanisms and the non-medical approach to

enhance HDL cholesterol[J/OL]. Front Physiol，2018，

9：526. https：//doi.org/10.3389/fphys.2018.00526.

[8] PÉREZ-MÉNDEZ Ó，PACHECO H G，

MARTÍNEZ-SÁNCHEZ C，et al. HDL-cholesterol

in coronary artery disease risk：function or

structure?[J/OL]. Clin Chim Acta，2014，429：111-

122. https：//doi.org/10.1016/j.cca.2013.12.001.

[9] Pullicino P M. Pathogenesis of lacunar infarcts and

small deep infarcts[J]. Adv Neurol，1993，62：125-

140.

[10] RADER D J，ALEXANDER E T，WEIBEL G

L，et al. The role of reverse cholesterol transport

in animals and humans and relationship to

atherosclerosis[J]. J Lipid Res，2009，50（Suppl）：

S189-S194.

[11] ROSENSON R S，BREWER H B Jr，DAVIDSON

W S，et al. Cholesterol efflux and atheroprotection：

advancing the concept of reverse cholesterol

transport[J]. Circulation，2012，125（15）：1905-1919.

[12] NOFER J R. Signal transduction by HDL：agonists，

receptors，and signaling cascades[J/OL]. Handb

Exp Pharmacol，2015，224：229-256. https：//doi.

org/10.1007/978-3-319-09665-0_6.

[13] TRIGATTI B L，FULLER M. HDL signaling and

protection against coronary artery atherosclerosis in

mice[J]. J Biomed Res，2016，30（2）：94-100.

[14] GAO M，ZHAO D，SCHOUTEDEN S，et

al. Regulation of high-density lipoprotein on hematopoietic stem/progenitor cells in

atherosclerosis requires scavenger receptor type BI

expression[J]. Arterioscler Thromb Vasc Biol，2014，

34（9）：1900-1909.

[15] SAITO I，YAMAGISHI K，KOKUBO Y，et al.

Association of high-density lipoprotein cholesterol

concentration with different types of stroke and

coronary heart disease：The Japan Public Health

Center-based prospective（JPHC）study[J/OL].

Atherosclerosis，2017，265：147-154. https：//doi.

org/10.1016/j.atherosclerosis.2017.08.032.

[16] MENG G L，TAN Y，FANG M，et al. Paradoxical

elevation of high density lipoprotein cholesterol in

association with lacunar-type cerebral infarction[J/

OL]. Med Sci Monit，2015，21：1872-1878. https：//

doi.org/10.12659/MSM.893647.

[17] BAKKER S L，DE LEEUW F E，KOUDSTAAL

P J，et al. Cerebral CO2 reactivity，cholesterol，and

high-density lipoprotein cholesterol in the elderly[J].

Neurology，2000，54（4）：987-989.

[18] TIRSCHWELL D L，SMITH N L，HECKBERT S

R，et al. Association of cholesterol with stroke risk

varies in stroke subtypes and patient subgroups[J].

Neurology，2004，63（10）：1868-1875.

[19] HINDY G，ENGSTRÖM G，LARSSON S C，et al.

Role of blood lipids in the development of ischemic

stroke and its subtypes：a Mendelian Randomization

Study[J]. Stroke，2018，49（4）：820-827.

[20] PIKULA A，BEISER A S，WANG J，et al. Lipid and

lipoprotein measurements and the risk of ischemic

vascular events：Framingham Study[J]. Neurology，

2015，84（5）：472-479.

[21] TONI D，DI ANGELANTONIO E，DI MASCIO

M T，et al. Types of stroke recurrence in patients

with ischemic stroke：a substudy from the PRoFESS

trial[J]. Int J Stroke，2014，9（7）：873-878.

[22] ESTRUCH R，ROS E，SALAS-SALVADÓ J，et al.

Primary prevention of cardiovascular disease with a

Mediterranean diet[J]. N Engl J Med，2013，368（14）：

1279-1290.

[23] CHEN G C，NEELAKANTAN N，MARTÍNCALVO

N，et al. Adherence to the Mediterranean

diet and risk of stroke and stroke subtypes[J]. Eur J

Epidemiol，2019，34（4）：337-349.

[24] TUTTOLOMONDO A，CASUCCIO A，BUTTÀ

C，et al. Mediterranean Diet in patients with

acute ischemic stroke：relationships between

Mediterranean Diet score，diagnostic subtype，and

stroke severity index[J]. Atherosclerosis，2015，243

（1）：260-267.

[25] RONDANELLI M，GIACOSA A，MORAZZONI

P，et al. MediterrAsian diet products that could

raise HDL-cholesterol：a systematic review[J/OL].

Biomed Res Int，2016，2016：2025687. http：//dx.doi.

org/10.1155/2016/2025687.

[26] MILLAR C L，DUCLOS Q，BLESSO C N. Effects

of dietary flavonoids on reverse cholesterol transport，

HDL metabolism，and HDL function[J]. Adv Nutr，

2017，8（2）：226-239.

[27] RUIZ-RAMIE J J，BARBER J L，SARZYNSKI M

A. Effects of exercise on HDL functionality[J]. Curr

Opin Lipidol，2019，30（1）：16-23.

[28] RAHMATI-AHMADABAD S，BROOM D R，

GHANBARI-NIAKI A，et al. Effects of exercise on

reverse cholesterol transport：a systemized narrative

review of animal studies[J/OL]. Life Sci. 2019，224：

139-148. https：//doi.org/10.1016/j.lfs.2019.03.058.

[29] GARELNABI M，MAHINI H，WILSON T.

Quercetin intake with exercise modulates lipoprotein

metabolism and reduces atherosclerosis plaque

formation[J/OL]. J Int Soc Sports Nutr，2014，11：22.

https：//doi.org/10.1186/1550-2783-11-22.

[30] PINTO P R，DA SILVA K S，IBORRA R T，et

al. Exercise training favorably modulates gene and

protein expression that regulate arterial cholesterol

content in CETP transgenic mice[J/OL]. Front

Physiol，2018，9：502. https：//doi.org/10.3389/

fphys.2018.00502.

[31] AMARENCO P，BOGOUSSLAVSKY J，

CALLAHAN A 3rd，et al. High-dose atorvastatin

after stroke or transient ischemic attack[J]. N Engl J

Med，2006，355（6）：549-555.

[32] AMARENCO P，LABREUCHE J. Lipid

management in the prevention of stroke：review

and updated meta-analysis of statins for stroke

prevention[J]. Lancet Neurol，2009，8（5）：453-463.

[33] HOSOMI N，NAGAI Y，KOHRIYAMA T，et al.

The Japan Statin Treatment Against Recurrent Stroke

（J-STARS）：a multicenter，randomized，open-label，

parallel-group study[J]. EBio Medicine，2015，2（9）：

1071-1078.

[34] CASTILLA-GUERRA L，FERNANDEZMORENO

M D C，LEON-JIMENEZ D，et al.

Statins in ischemic stroke prevention：what have we

learned in the post-SPARCL（The Stroke Prevention

by Aggressive Reduction in Cholesterol Levels）

decade?[J]. Curr Treat Options Neurol，2019，21（5）：

22.

[35] TENENBAUM A，MOTRO M，FISMAN E Z，et

al. Bezafibrate for the secondary prevention of

myocardial infarction in patients with metabolic

syndrome[J]. Arch Intern Med，2005，165（10）：1154-1160.

[36] WANG D，LIU B，TAO W，et al. Fibrates for

secondary prevention of cardiovascular disease

and stroke[J/OL]. Cochrane Database Syst

Rev，2015，2015（10）：CD009580. https：//doi.

org/10.1002/14651858.CD009580.pub2.

[37] TAYLOR A J，VILLINES T C，STANEK E J，et

al. Extended-release niacin or ezetimibe and carotid

intima-media thickness[J]. N Engl J Med，2009，361

（22）：2113-2122.

[38] AIM-HIGH Investigators，BODEN W E，

PROBSTFIELD J L，et al. Niacin in patients with

low HDL cholesterol levels receiving intensive statin

therapy[J]. N Engl J Med，2011，365（24）：2255-

2267.

[39] HPS2-THRIVE Collaborative Group. HPS2-

THRIVE randomized placebo-controlled trial in 25

673 high-risk patients of ER niacin/laropiprant：trial

design，pre-specified muscle and liver outcomes，

and reasons for stopping study treatment[J]. Eur

Heart J，2013，34（17）：1279-1291.

[40] PROBSTFIELD J L，BODEN W E，ANDERSON

T，et al. Cardiovascular outcomes during extended

follow-up of the AIM-HIGH trial cohort[J]. J Clin

Lipidol，2018，12（6）：1413-1419.

[41] BODEN W E，SIDHU M S，TOTH P P. The

therapeutic role of niacin in dyslipidemia

management[J]. J Cardiovasc Pharmacol Ther，2014，

19（2）：141-158.

[42] BARTER P J，CAULFIELD M，ERIKSSON M，et

al. Effects of torcetrapib in patients at high risk for

coronary events[J]. N Engl J Med，2007，357（21）：

2109-2122.

[43] SCHWARTZ G G，OLSSON A G，ABT M，et al.

Effects of dalcetrapib in patients with a recent acute

coronary syndrome[J]. N Engl J Med，2012，367

（22）：2089-2099.

[44] LINCOFF A M，NICHOLLS S J，RIESMEYER J

S，et al. Evacetrapib and cardiovascular outcomes

in high-risk vascular disease[J]. N Engl J Med，2017，

376（20）：1933-1942.

[45] HPS3/TIMI55-REVEAL Collaborative Group，

BOWMAN L，HOPEWELL J C，et al. Effects of

anacetrapib in patients with atherosclerotic vascular

disease[J]. N Engl J Med，2017，377（13）：1217-

1227.

[46] TALL A R，RADER D J. Trials and tribulations of

CETP inhibitors[J]. Circ Res，2018，122（1）：106-

112.

[47] BOHULA E A，WIVIOTT S D，GIUGLIANO R

P，et al. Prevention of stroke with the addition of

Ezetimibe to statin therapy in patients with acute

coronary syndrome in IMPROVE-IT（Improved

Reduction of Outcomes：Vytorin Efficacy

International Trial）[J]. Circulation. 2017，136（25）：

2440-2450.

[48] ADACHI H，NAKANO H，YAMAMOTO K，et

al. Ezetimibe ameliorates atherogenic lipids profiles，

insulin resistance and hepatocyte growth factor in

obese patients with hypercholesterolemia[J]. Lipids

Health Dis，2015，14（1）：1.

[49] AI C，ZHANG S，HE Q，et al. Comparing the

combination therapy of ezetimibe and atorvastatin

with atorvastatin monotherapy for regulating blood

lipids：a systematic review and meta-analyse[J].

Lipids Health Dis，2018，17（1）：239.

[50] EASTON R，GILLE A，D'ANDREA D，et al. A

multiple ascending dose study of CSL112，an

infused formulation of ApoA-Ⅰ[J]. J Clin Pharmacol，

2014，54（3）：301-310.

[51] TRICOCI，D'ANDREA D M，GURBEL P A，et al.

Infusion of reconstituted high-density lipoprotein，

CSL112，in patients with atherosclerosis：safety and

pharmacokinetic results from a phase 2a randomized

clinical trial[J]. J Am Heart Assoc，2015，4（8）：

e002171. https：//doi.org/10.1161/JAHA.115.002171.

[52] MICHAEL GIBSON C，KORJIAN S，TRICOCI

P，et al. Safety and Tolerability of CSL112，a

Reconstituted，Infusible，Plasma-Derived

Apolipoprotein A-I，After Acute Myocardial

Infarction：The AEGIS-I Trial（ApoA-I Event

Reducing in Ischemic Syndromes I）[J]. Circulation，

2016，134（24）：1918-1930.

[53] KARALIS I，JUKEMA J W. HDL mimetics

infusion and regression of atherosclerosis：is it

still considered a valid therapeutic option?[J]. Curr

Cardiol Rep，2018，20（8）：66.